GENSIGHT BIOLOGICS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4195 EUR | +0.36% |
|
+2.32% | -8.80% |
| Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
| Mar. 25 | GenSight: share price falls, limited financial visibility | CF |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 81.14 | 304.4 | 255.4 | 155.2 | 25.66 | 32.73 | - | - |
| Enterprise Value (EV) 1 | 73.47 | 285.5 | 231.1 | 162.4 | 25.66 | 90.53 | 118.4 | 156.7 |
| P/E ratio | -2.3 x | -7.35 x | -8.83 x | -5.6 x | -0.85 x | -0.74 x | -0.75 x | -0.53 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 16.6 x | 41.1 x | 33.2 x | 31.7 x | 8.55 x | 7.44 x | 4.42 x | 5.74 x |
| EV / Revenue | 15 x | 38.6 x | 30 x | 33.2 x | 8.55 x | 20.6 x | 16 x | 27.5 x |
| EV / EBITDA | -2.51 x | -11.9 x | -8.5 x | -6.07 x | -0.93 x | -3.61 x | -5.33 x | -5.24 x |
| EV / FCF | -2.61 x | -19 x | -13.5 x | -4.78 x | - | -3.19 x | -4.23 x | -4.1 x |
| FCF Yield | -38.4% | -5.27% | -7.43% | -20.9% | - | -31.4% | -23.6% | -24.4% |
| Price to Book | 6.93 x | 28.1 x | 21.9 x | -10.2 x | - | -0.3 x | -0.2 x | -0.14 x |
| Nbr of stocks (in thousands) | 32,653 | 42,686 | 45,931 | 46,162 | 55,792 | 78,027 | - | - |
| Reference price 2 | 2.485 | 7.130 | 5.560 | 3.362 | 0.4600 | 0.4195 | 0.4195 | 0.4195 |
| Announcement Date | 3/12/20 | 3/10/21 | 4/8/22 | 3/24/23 | 3/22/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.9 | 7.4 | 7.7 | 4.9 | 3 | 4.4 | 7.4 | 5.7 |
| EBITDA 1 | -29.31 | -24.01 | -27.2 | -26.77 | -27.52 | -25.1 | -22.2 | -29.9 |
| EBIT 1 | -30.3 | -24.9 | -28.1 | -27.8 | -29.7 | -26.2 | -23.2 | -31 |
| Operating Margin | -618.37% | -336.49% | -364.94% | -567.35% | -990% | -595.45% | -313.51% | -543.86% |
| Earnings before Tax (EBT) | -30.71 | -34.01 | -28.62 | -27.62 | - | - | - | - |
| Net income 1 | -30.7 | -34 | -28.6 | -27.6 | -26.2 | -26 | -25.6 | -35.8 |
| Net margin | -626.53% | -459.46% | -371.43% | -563.27% | -873.33% | -590.91% | -345.95% | -628.07% |
| EPS 2 | -1.080 | -0.9700 | -0.6300 | -0.6000 | -0.5400 | -0.5700 | -0.5600 | -0.7900 |
| Free Cash Flow 1 | -28.18 | -15.05 | -17.17 | -34 | - | -28.4 | -28 | -38.2 |
| FCF margin | -575.12% | -203.38% | -223% | -693.98% | - | -645.45% | -378.38% | -670.18% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/10/21 | 4/8/22 | 3/24/23 | 3/22/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 7.25 | - | 57.8 | 85.7 | 124 |
| Net Cash position 1 | 7.67 | 18.8 | 24.2 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.2708 x | - | -2.303 x | -3.86 x | -4.147 x |
| Free Cash Flow 1 | -28.2 | -15.1 | -17.2 | -34 | - | -28.4 | -28 | -38.2 |
| ROE (net income / shareholders' equity) | -172% | -307% | -206% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.3600 | 0.2500 | 0.2500 | -0.3300 | - | -1.410 | -2.050 | -2.910 |
| Cash Flow per Share | -0.9900 | - | - | - | - | - | - | - |
| Capex 1 | 0.07 | 0.01 | 0.03 | 0.25 | - | 0.1 | 0.1 | 0.1 |
| Capex / Sales | 1.41% | 0.08% | 0.42% | 5.14% | - | 2.27% | 1.35% | 1.75% |
| Announcement Date | 3/12/20 | 3/10/21 | 4/8/22 | 3/24/23 | 3/22/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.4195
EUR
Average target price
0.4
EUR
Spread / Average Target
-4.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.80% | 34.94M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SIGHT Stock
- Financials GenSight Biologics S.A.
